Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10516 in VHL Syndrome Associated Tumors
NCT06553339Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-10516 in von Hippel-Lindau syndrome (VHL) and clear cell renal cell carcinoma (ccRCC) (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose / Maximum Acceptable Dose at 2 months and Objective Response Rate at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
HS-10516
03
Conditions
von Hippel-Lindau syndrome (VHL)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06553339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553339.